Document detail
ID
oai:pubmedcentral.nih.gov:1053...
Topic
Short ReportAuthor
Ray, Jason Raviskanthan, SubahariLangue
enEditor
BMJ Publishing Group
Category
BMJ Neurology Open
Year
2023
listing date
12/13/2023
Keywords
onabotulinumtoxina prospective injections vas medicine tolerability improve study musicAbstract
INTRODUCTION: OnabotulinumtoxinA for migraine involves 31 injected repeated every 12 weeks.
Tolerability is a significant factor impacting discontinuation.
Music medicine has not been studied previously as an intervention to improve the tolerability of injections.
METHODOLOGY: A single-centre prospective cohort study was undertaken.
Following baseline, patients had music played during the procedure.
Change in Visual Analogue Score (VAS) was assessed as the primary outcome.
RESULTS: Over 6 months, 50 patients were recruited with a median age of 42, and median duration of therapy of 13.5 months.
‘Quiet calm classical music’ was associated with a significant reduction in VAS (z=−4.7, p<0.001).
Duration of therapy, disease state or headache frequency had no correlation with change in VAS.
CONCLUSION: Music medicine is associated with a significant reduction in the procedural pain of onabotulinumtoxinA injections in prospective study.
Further study is required to explore other modifiable factors to improve patient experience.
Ray, Jason,Raviskanthan, Subahari, 2023, Music medicine to improve the tolerability of onabotulinumtoxinA injections for chronic migraine: an open-label prospective cohort study, BMJ Publishing Group
Neurological manifestation in COVID-19 disease with neuroimaging studies
neuroimaging neurological covid-19
